All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
Alector (FTD)
This project is being done to determine if the experimental drug AL001 is effective and safe in treating individuals who have a known progranulin gene mutation that causes FTD, when compared to placebo (a solution that contains no active AL001 drug).
General Eligibility
- Known pre-symptomatic or symptomatic carriers of a heterozygous loss-of-function GRN mutation causative of FTD
- 18 – 85 years old
- Suitable study partner
PLEASE consult Dr. Granadillo to send patient for genetic counseling and testing for the GRN mutation. This is for clinical purposes and not part of the research ...
ADvance II (probable AD mild)
The ADvance II Study is researching the use of deep brain stimulation of the fornix (known as DBS-f), a place in the brain that plays a central role in memory, in people with Alzheimer’s disease.
DBS-f uses a surgically implanted medical device, similar to a heart pacemaker, to deliver mild electrical pulses to precisely targeted areas of the brain.
General Eligibility
- At least 65 years old with Probable Alzheimer’s disease mild
- Has an available caregiver or other appropriate knowledgeable informant
- Must be a good surgical candidate for placement of a deep brain stimulator
- Eit ...
Network-Level Mechanisms for Preclinical Alzheimer’s Disease Development
In this study we want to find out whether the use of AGB101 (220 mg of levetiracetam in an extended release form) in healthy adults with the APOE 4 gene can reduce overactive brain activity in the part of the brain called the hippocampus. We also want to study whether there is a correlation with improved memory function.
Primary Investigator: Shi-Jiang Li, PhD
Status: Currently Enrolling
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
The purpose of this Phase 3 study is to determine if the experimental drug AL001 is effective and safe in treating individuals who have a known progranulin gene mutation that causes frontotemporal dementia (FTD), when compared to placebo (a solution that contains no active AL001 drug).
Primary Investigator: Elias Granadillo, MD
Status: Currently Enrolling
ADvance II: A 12-month double-blind, randomized, controlled study to evaluate the safety and efficacy of Deep Brain Stimulation of the fornix (DBS-f) in patients with mild probable Alzheimer’s Disease, PRO FNMI-002
The purpose of this study is to see what benefits and associated risks of deep brain stimulation of the fornix (DBS-f) exist in patients with mild Alzheimer’s disease (AD).
DBS therapy consists of leads (wires) or electrodes designed to target specific areas of the brain and are connected to a power source (generator or battery) implanted (placed) under the skin in your chest near the collarbone. This study will look at the effects in patients with mild Alzheimer’s disease who are already taking medication for the treatment of AD.
Primary Investigator: Malgorzata Franczak, MD
Status: ...
TREAT MS: Traditional versus Early Aggressive Therapy for Multiple Sclerosis (TREATMS) Trial
The purpose of this research is to identify the most appropriate treatment strategy for people with multiple sclerosis (MS), especially shortly after diagnosis when it may be most possible to increase a patient’s chance for preventing longer-term disability.
The TREAT-MS study will help inform patients and the broader health care community on whether patients would most benefit from an earlier, aggressive therapy or if starting with a traditional therapy, followed by a switch if relapses or new MRI lesions occur, is the best approach to preventing long-term disability.
Principal ...
EXCHANGE: Safety and tolerability of conversion from oral or injectable disease modifying therapies to dose-titrated Oral Siponimod in patients with advancing forms of relapsing multiple sclerosis: A 6-month open label, multi-center Phase IIIb study
In this study we want to find out how safe Siponimod is and how well you tolerate to the drug. The results of this study will help doctors decide if and when to switch patients from other MS medicines (also known as disease modifying therapies or DMTs) to Siponimod.
On March 26, 2019, Siponimod was approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of MS under the brand name Mayzent®. Siponimod may have advantages over DMTs, but we won’t know until we do more research studies.
Principal Investigator: Ahmed Obeidat, MD, PhD
Status: Currently ...
Celegene: A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod(RPC-1063)
The purpose of this study is to learn about changes in cognition that happen while taking the study medication RPC-1063, also known as Ozanimod. Everyone that participates in this study will receive Ozanimod, which is an experimental drug. “Experimental” means that the study drug is still being tested for safety and effectiveness and is not approved for sale in the United States by the Food and Drug Administration (FDA).
Principal Investigator: Ahmed Obeidat, MD, PhD
Status: Currently Enrolling
Using Art to Increase Health Literacy of Physical Activity in Patients With Parkinson Disease
The purpose of this program is to use creative art (visual or movement based) to increase health literacy in the area of physical activity recommendations for individuals who have Parkinson’s Disease.
Primary Investigator: Ryan Brennan, DO
Utilization of Target Ranges to Treat Patients With Parkinson’s Disease by Objective Measurement Using the Personal KinetiGraph (PKG) Compared to Standard of Care Assessment (TARGET-PD)
The purpose of this project is to evaluate whether patients with Parkinson’s disease who are managed with standard of care and the aid of target ranges reported on the PKG have improved Parkinson’s disease symptoms and outcomes compared to patients treated only with standard of care.
Primary Investigator: Ryan Brennan, DO
A 52-Week, Open-Label, Single-Arm Study to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson’s Disease.
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI (subcutaneous injection) for 24 hours daily for up to 52 weeks.
Primary Investigator: Ryan Brennan, DO
A Randomized, Double-Blind, Placebo-Controlled Trial of Urate Elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson’s Disease
To determine whether oral inosine dosed to moderately elevate serum urate over 2 years slows clinical decline in early Parkinson’s Disease.
Primary Investigator: Karen Blindauer, MD
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two-Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants w/ Parkinson’s Disease
The primary objective of this two-cohort study is to assess the safety and tolerability of the daily oral administration of Nilotinib or placebo in participants with moderate to advanced PD (Cohort 1) and in participants with early/de novo PD (Cohort 2). Participants in Cohort 2 will be treated with the selected dose determined in Cohort 1 or matching placebo. Cohort 1 will be treated with Nilotinib 150mg, 300mg, or matching placebo.
Primary Investigator: Karen Blindauer, MD
SPARK-PD - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BIIB054 in Subjects With Parkinson’s Disease
The primary objective of this study is to evaluate the dose-related safety of BIIB054. There is a placebo-controlled treatment period (48 weeks) followed by a dose-blinded active treatment (48 weeks).
Primary Investigator: Karen Blindauer, MD
A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of 36 Weeks Treatment With NLY01 in Early-Stage Parkinson’s Disease
Primary Investigator: Karen Blindauer, MD
Status: Starting up
Structural and Functional Connectivity Changes in the Brain in Response to Diagnostic Nerve Blocks in Stroke Survivors
Identify changes in brain functional connectivity associated with diagnostic nerve blocks (DNB) to relieve spasticity in stroke survivors.
Primary Investigator: John McGuire, MD
Status: Currently Enrolling
IPSEN Abolish: Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort (AboLiSh)
Observational study to assess the longitudinal attainment of person centered and function related goals after one or more abobotulinum toxin A (aboBoNT-A) injections in the lower limb using the cumulated Goal Attainment Scaling -Leg (GASleg) T score in a real life clinical setting.
Primary Investigator: Nicholas Ketchum, MD
Status: Currently Enrolling
Merz: Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke (PLUS)
To test the safety and efficacy of NT 201 (Xeomin) for treating lower limb spasticity caused by stroke or traumatic brain injury in adult subjects, followed by an open label extension with or without combined upper limb treatment
Primary Investigator: Nicholas Ketchum, MD
Status: Currently Enrolling
SleepSmart: The Sleep for Stroke Management and Recovery Trial
Designed to evaluate ischemic stroke patients or patients with transient ischemic attack (TIA) for obstructive sleep apnea. Patients who qualify, will help assess whether continuous positive airway pressure (CPAP) for obstructive sleep apnea, after stroke, helps with recovery or helps prevent another stroke.
Status: Currently enrolling
ARCADIA: Atrial Cardiopathy and Antithrombotic Drugs in Prevention after Cryptogenic Stroke
A randomized, controlled trial of anticoagulation with Apixaban versus Aspirin for patients with embolic stroke of undetermined source, or ESUS, and evidence of atrial cardiopathy.
Status: Currently enrolling
Progesterone for Traumatic Brain Injury; Experimental Clinical Treatment (PROTECT)
Keywords
TBI, Exception from Informed Consent